BlackRock Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

BlackRock Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$866K	Buy	57,381 +1,302	+2%	+$18.4K	﹤0.01%	2189
2016 Q3	$854K	Sell	56,079 -429,541	-88%	-$17.4M	﹤0.01%	2105
2016 Q2	$18.9M	Sell	485,620 -187	-0%	-$6.72K	0.01%	783
2016 Q1	$13.5M	Buy	485,807 +46,327	+11%	+$1.54M	0.01%	859
2015 Q4	$23.6M	Buy	439,480 +11,729	+3%	+$592K	0.01%	744
2015 Q3	$17.1M	Buy	427,751 +288,054	+206%	+$9.39M	0.01%	800
2015 Q2	$4.46M	Sell	139,697 -145,250	-51%	-$3.68M	﹤0.01%	1178
2015 Q1	$6.8M	Sell	284,947 -55,986	-16%	-$1.25M	﹤0.01%	1046
2014 Q4	$6.02M	Hold	340,933	–	–	﹤0.01%	1073
2014 Q3	$4.67M	Hold	340,933	–	–	﹤0.01%	1118
2014 Q2	$5.75M	Hold	340,933	–	–	﹤0.01%	1083
2014 Q1	$6.2M	Buy	+340,933	New	+$6.15M	﹤0.01%	1052

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Group's ITCI Position: Q4 2016 in Review

BlackRock Group increased its Intra-Cellular Therapies Inc. (ITCI) stake by 2.3% in Q4 2016, buying an estimated $18.4K and bringing the position to 57,381 shares worth $866K. The position accounts for ﹤0.01% of the portfolio, ranked #2189.

BlackRock Group first reported a position in ITCI in Q1 2014 and has held it in 12 quarters since. The position peaked at $23.6M in Q4 2015. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

BlackRock Group held 57,381 shares of Intra-Cellular Therapies Inc. worth $866K as of Q4 2016.
BlackRock Group bought 1,302 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $18.4K.
Intra-Cellular Therapies Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2189 holding.
BlackRock Group first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Group's Intra-Cellular Therapies Inc. position peaked at $23.6M in Q4 2015.
129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.